Adda Grimberg1, David B Allen. 1. aDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania bDivision of Endocrinology and Diabetes, The Children's Hospital of Philadelphia cLeonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania dDepartment of Pediatrics, University of Wisconsin School of Medicine and Public Health eDivision of Endocrinology and Diabetes, American Family Children's Hospital, Madison, Wisconsin, USA.
Abstract
PURPOSE OF REVIEW: The Pediatric Endocrine Society recently published new guidelines for the use of human growth hormone (hGH) and human insulin-like growth factor-I (hIGF-I) treatment for growth hormone deficiency, idiopathic short stature, and primary IGF-I deficiency in children and adolescents. This review places the new guidelines in historical contexts of the life cycle of hGH and the evolution of US health care, and highlights their future implications. RECENT FINDINGS: The new hGH guidelines, the first to be created by the Grading of Recommendations Assessment, Development and Evaluation approach, are more conservative than their predecessors. They follow an extended period of hGH therapeutic expansion at a time when US health care is pivoting toward value-based practice. There are strong supporting evidence and general agreement regarding the restoration of hormonal normalcy in children with severe deficiency of growth hormone or hIGF-I. More complex are issues related to hGH treatment to increase growth rates and heights of otherwise healthy short children with either idiopathic short stature or 'partial' isolated idiopathic growth hormone deficiency. SUMMARY: The guidelines-developing process revealed fundamental questions about hGH treatment that still need evidence-based answers. Unless and until such research is performed, a more restrained hGH-prescribing approach is appropriate.
PURPOSE OF REVIEW: The Pediatric Endocrine Society recently published new guidelines for the use of humangrowth hormone (hGH) and humaninsulin-like growth factor-I (hIGF-I) treatment for growth hormone deficiency, idiopathic short stature, and primary IGF-I deficiency in children and adolescents. This review places the new guidelines in historical contexts of the life cycle of hGH and the evolution of US health care, and highlights their future implications. RECENT FINDINGS: The new hGH guidelines, the first to be created by the Grading of Recommendations Assessment, Development and Evaluation approach, are more conservative than their predecessors. They follow an extended period of hGH therapeutic expansion at a time when US health care is pivoting toward value-based practice. There are strong supporting evidence and general agreement regarding the restoration of hormonal normalcy in children with severe deficiency of growth hormone or hIGF-I. More complex are issues related to hGH treatment to increase growth rates and heights of otherwise healthy short children with either idiopathic short stature or 'partial' isolated idiopathic growth hormone deficiency. SUMMARY: The guidelines-developing process revealed fundamental questions about hGH treatment that still need evidence-based answers. Unless and until such research is performed, a more restrained hGH-prescribing approach is appropriate.
Authors: Pablo Alonso-Coello; Andrew D Oxman; Jenny Moberg; Romina Brignardello-Petersen; Elie A Akl; Marina Davoli; Shaun Treweek; Reem A Mustafa; Per O Vandvik; Joerg Meerpohl; Gordon H Guyatt; Holger J Schünemann Journal: BMJ Date: 2016-06-30
Authors: D B Allen; P Backeljauw; M Bidlingmaier; B M K Biller; M Boguszewski; P Burman; G Butler; K Chihara; J Christiansen; S Cianfarani; P Clayton; D Clemmons; P Cohen; F Darendeliler; C Deal; D Dunger; E M Erfurth; J S Fuqua; A Grimberg; M Haymond; C Higham; K Ho; A R Hoffman; A Hokken-Koelega; G Johannsson; A Juul; J Kopchick; P Lee; M Pollak; S Radovick; L Robison; R Rosenfeld; R J Ross; L Savendahl; P Saenger; H T Sorensen; K Stochholm; C Strasburger; A Swerdlow; M Thorner Journal: Eur J Endocrinol Date: 2015-11-12 Impact factor: 6.664
Authors: Adda Grimberg; Lina Huerta-Saenz; Robert Grundmeier; Mark Jason Ramos; Susmita Pati; Andrew J Cucchiara; Virginia A Stallings Journal: Sci Rep Date: 2015-06-09 Impact factor: 4.379
Authors: Shanlee Davis; Meredith A Ware; Jordan Zeiger; Matthew A Deardorff; Katheryn Grand; Adda Grimberg; Stephanie Hsu; Megan Kelsey; Shideh Majidi; Revi P Matthew; Melanie Napier; Natalie Nokoff; Chitra Prasad; Andrew C Riggs; Margaret L McKinnon; Ghayda Mirzaa Journal: Am J Med Genet A Date: 2019-11-15 Impact factor: 2.802
Authors: Camilia Kamoun; Colin Patrick Hawkes; Hareesh Gunturi; Andrew Dauber; Joel N Hirschhorn; Adda Grimberg Journal: Horm Res Paediatr Date: 2021-10-18 Impact factor: 4.275
Authors: Talia Hitt; Kenneth R Ginsburg; Pamela Cousounis; Terri H Lipman; Andrew J Cucchiara; Virginia A Stallings; Adda Grimberg Journal: Horm Res Paediatr Date: 2020-03-31 Impact factor: 2.852
Authors: Laura Penta; Marta Cofini; Laura Lucchetti; Letizia Zenzeri; Alberto Leonardi; Lucia Lanciotti; Daniela Galeazzi; Alberto Verrotti; Susanna Esposito Journal: Int J Environ Res Public Health Date: 2019-01-23 Impact factor: 3.390